JP6261621B2 - アルファ−シヌクレイン抗体及びその使用 - Google Patents

アルファ−シヌクレイン抗体及びその使用 Download PDF

Info

Publication number
JP6261621B2
JP6261621B2 JP2015559593A JP2015559593A JP6261621B2 JP 6261621 B2 JP6261621 B2 JP 6261621B2 JP 2015559593 A JP2015559593 A JP 2015559593A JP 2015559593 A JP2015559593 A JP 2015559593A JP 6261621 B2 JP6261621 B2 JP 6261621B2
Authority
JP
Japan
Prior art keywords
antibody
fragment
synuclein
syn
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015559593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016511254A5 (cg-RX-API-DMAC7.html
JP2016511254A (ja
Inventor
エル−アグナフ，オマル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Arab Emirates University
Original Assignee
United Arab Emirates University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/781,158 external-priority patent/US20140241987A1/en
Application filed by United Arab Emirates University filed Critical United Arab Emirates University
Publication of JP2016511254A publication Critical patent/JP2016511254A/ja
Publication of JP2016511254A5 publication Critical patent/JP2016511254A5/ja
Application granted granted Critical
Publication of JP6261621B2 publication Critical patent/JP6261621B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
JP2015559593A 2013-02-28 2014-02-27 アルファ−シヌクレイン抗体及びその使用 Active JP6261621B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/781,158 US20140241987A1 (en) 2013-02-28 2013-02-28 Alpha-synuclein antibodies and uses thereof
US13/781,158 2013-02-28
US14/138,347 2013-12-23
US14/138,347 US9534044B2 (en) 2013-02-28 2013-12-23 Alpha-synuclein antibodies and uses thereof
PCT/IB2014/059287 WO2014132210A1 (en) 2013-02-28 2014-02-27 Alpha-synuclein antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2016511254A JP2016511254A (ja) 2016-04-14
JP2016511254A5 JP2016511254A5 (cg-RX-API-DMAC7.html) 2017-03-30
JP6261621B2 true JP6261621B2 (ja) 2018-01-17

Family

ID=51388371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015559593A Active JP6261621B2 (ja) 2013-02-28 2014-02-27 アルファ−シヌクレイン抗体及びその使用

Country Status (6)

Country Link
US (2) US9534044B2 (cg-RX-API-DMAC7.html)
EP (1) EP2961774B1 (cg-RX-API-DMAC7.html)
JP (1) JP6261621B2 (cg-RX-API-DMAC7.html)
KR (1) KR101990096B1 (cg-RX-API-DMAC7.html)
CN (1) CN105121473B (cg-RX-API-DMAC7.html)
WO (1) WO2014132210A1 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015314783B2 (en) * 2014-09-11 2021-10-21 Amprion, Inc. Detection of misfolded proteins
EP3207057A2 (en) * 2014-10-16 2017-08-23 F. Hoffmann-La Roche AG Anti-alpha-synuclein antibodies and methods of use
EP3961216B1 (en) * 2014-11-14 2024-02-14 United Arab Emirates University Dihydromyricetin for use as imaging agent
ES2904573T3 (es) 2015-03-27 2022-04-05 Univ Southern California Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
CN107847601A (zh) 2015-06-04 2018-03-27 南加利福尼亚大学 Lym‑1和lym‑2靶向的car细胞免疫疗法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10160800B2 (en) * 2016-06-02 2018-12-25 Medimmune Limited Antibodies to α-synuclein and uses thereof
US10245320B2 (en) 2016-09-30 2019-04-02 Enzo Biochem, Inc. Immunomodulatory pharmaceutical compositions and methods of use thereof
MA46836A (fr) 2016-11-15 2019-09-25 H Lundbeck As Agents, utilisations et procédés pour le traitement d'une synucléinopathie
CN110072888B (zh) 2016-12-16 2023-07-18 H.隆德贝克有限公司 药剂、用途和方法
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3567054A4 (en) * 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
MX2019008029A (es) * 2017-01-06 2019-12-11 Abl Bio Inc Anticuerpo anti-alfa-sinucleina y su uso.
EP3583124A1 (en) * 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
WO2018204352A1 (en) 2017-05-01 2018-11-08 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
WO2019018607A1 (en) * 2017-07-20 2019-01-24 Enzo Biochem, Inc. IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF
WO2019040617A1 (en) 2017-08-23 2019-02-28 The Trustees Of The University Of Pennsylvania MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHODS USING SAME
EP3684463B1 (en) 2017-09-19 2025-05-14 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
AU2018370279B2 (en) * 2017-11-17 2022-11-03 Abl Bio Inc. Antibodies to a-synuclein and uses thereof
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
JP7212391B2 (ja) * 2017-12-14 2023-01-25 エービーエル バイオ インコーポレイテッド ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
WO2019133997A1 (en) 2017-12-31 2019-07-04 Neuroenhancement Lab, LLC System and method for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
CN113382683A (zh) 2018-09-14 2021-09-10 纽罗因恒思蒙特实验有限责任公司 改善睡眠的系统和方法
EP3861015A4 (en) 2018-10-07 2022-11-23 The University of British Columbia CONFORMATION SPECIFIC EPITOPES IN ALPHA-SYNUCLEIN, ANTIBODIES DIRECTED AGAINST AND METHODS THEREOF
JP2022520106A (ja) 2019-02-15 2022-03-28 ユニバーシティ オブ サザン カリフォルニア Ｌｙｍ－１およびｌｙｍ－２抗体組成物ならびに改善されたｃａｒ構築物
US11208477B2 (en) 2019-04-01 2021-12-28 Novo Nordisk A/S Antibodies and use thereof
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
CN110172098B (zh) * 2019-05-27 2023-03-10 长春工业大学 抗α-突触核蛋白的单克隆抗体及其应用
EP3985022A4 (en) * 2019-06-14 2023-08-02 ABL Bio, Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ITS USE
CA3147606A1 (en) * 2019-07-16 2021-01-21 Washington University Anti-grp78 antibodies and method of use thereof
KR102277871B1 (ko) * 2019-12-17 2021-07-15 원광대학교산학협력단 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트
NL2025332B1 (en) * 2020-04-10 2021-10-26 Syngle Therapeutics B V Novel alpha-synuclein binding antibodies, or antigen binding portions thereof.
PH12022552829A1 (en) * 2020-06-26 2023-06-14 Bioarctic Ab Alpha-synuclein protofibril-binding antibodies
WO2022060236A1 (en) * 2020-09-17 2022-03-24 Qatar Foundation For Education, Science And Community Development ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES
US20230365665A1 (en) 2020-09-17 2023-11-16 Qatar Foundation For Education, Science And Community Development ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES
CN113912713B (zh) * 2021-12-15 2022-03-08 北京凯祥弘康生物科技有限公司 一种抗α-突触核蛋白的单克隆抗体及其应用
CN113912715B (zh) * 2021-12-15 2022-03-01 北京凯祥弘康生物科技有限公司 一种抗α-突触核蛋白抗体及其相关产品和应用
CN114853887B (zh) * 2022-03-08 2022-12-20 骏蓦(北京)生物科技有限公司 一种特异性结合α-突触核蛋白的抗体及其应用
CN115032400A (zh) * 2022-03-28 2022-09-09 首都医科大学附属北京天坛医院 α-突触核蛋白在辅助诊断神经退行性疾病中的用途
CN116286668A (zh) * 2023-02-13 2023-06-23 贵安新区康顺生物科技有限公司 一种杂交瘤细胞株及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106271A (en) * 1992-09-03 2008-03-20 Yeda Res & Dev Ligand to TNF 75P receptor and its preparation
US5948658A (en) * 1996-06-25 1999-09-07 The Trustees Of Columbia University In The City Of New York Anti-cocaine catalytic antibody
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
WO2005051307A2 (en) * 2003-11-20 2005-06-09 Medimmune, Inc. Epha2 agonistic monoclonal antibodies and methods of use thereof
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
CA2662340C (en) * 2006-09-08 2016-08-02 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
GB0716885D0 (en) 2007-08-30 2007-10-10 United Arab Emirates Universit Diagnostic agent
CN101570575B (zh) * 2008-04-30 2012-02-29 北京市肿瘤防治研究所 Sncg的单克隆抗体及其应用
EA030826B1 (ru) 2008-12-19 2018-10-31 Панима Фармасьютикалз Аг ЧЕЛОВЕЧЕСКИЕ АУТОАНТИТЕЛА ПРОТИВ α-СИНУКЛЕИНА
CN102574915B (zh) * 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
CN101692092B (zh) * 2009-09-24 2013-04-10 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法
ES2661925T3 (es) 2010-02-26 2018-04-04 Bioarctic Ab Anticuerpos de unión a las protofibrillas y su uso en métodos terapéuticos diagnósticos para la enfermedad de Parkinson, la demencia con cuerpos de Lewy y otras alfa-sinucleinopatías
DE102011008153B4 (de) 2011-01-08 2018-08-09 Aj Roboscreen Gmbh Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein
ES2699801T3 (es) 2011-06-23 2019-02-12 Biogen Int Neuroscience Gmbh Moléculas de unión anti-alfa sinucleína

Also Published As

Publication number Publication date
KR20160010402A (ko) 2016-01-27
CN105121473A (zh) 2015-12-02
CN105121473B (zh) 2019-11-12
KR101990096B1 (ko) 2019-06-19
WO2014132210A1 (en) 2014-09-04
US10208111B2 (en) 2019-02-19
US9534044B2 (en) 2017-01-03
US20140241984A1 (en) 2014-08-28
EP2961774A1 (en) 2016-01-06
EP2961774A4 (en) 2016-10-26
EP2961774B1 (en) 2021-12-29
US20170190765A1 (en) 2017-07-06
HK1217107A1 (zh) 2016-12-23
JP2016511254A (ja) 2016-04-14

Similar Documents

Publication Publication Date Title
JP6261621B2 (ja) アルファ−シヌクレイン抗体及びその使用
AU2011219414B2 (en) Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with Lewy bodies and other alpha-synucleinopathies
EP1546734B1 (en) N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
CN103502272B (zh) 识别Tau的磷酸化特异抗体
US9849165B2 (en) Oligomer-specific amyloid beta epitope and antibodies
JPWO2011045945A1 (ja) アミロイドβのターン構造を認識する抗体
BR112021006123A2 (pt) anticorpos anti-sinucleína
US20180134777A1 (en) Alpha-Synuclein Antibodies (11D12)
US20180134775A1 (en) Alpha-Synuclein Antibodies (7A11)
US20140241987A1 (en) Alpha-synuclein antibodies and uses thereof
US20180134776A1 (en) Alpha-Synuclein Antibodies (4H6)
KR102523019B1 (ko) 항-a베타 항체 및 이의 용도
JP7151985B2 (ja) 抗プロパノイル化アミロイドβタンパク質抗体
CN107074925B (zh) 用于预防和/或治疗亨廷顿氏病的物质和方法
KR20170087472A (ko) 아밀로이드 β의 22번 위치 및 23번 위치의 턴 구조를 극히 특이적으로 인식하는 항체
JP2022502369A (ja) α−シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法
JP7564882B2 (ja) Ａｒｅｇに対する抗体及びその用途
HK1217107B (en) Alpha-synuclein antibodies and uses thereof
JP2024512855A (ja) 抗アミロイドベータ抗体及びその使用方法
HK1231887A1 (en) Oligomer-specific amyloid beta epitope and antibodies
AU2016208334A1 (en) Oligomer-specific amyloid beta epitope and antibodies
HK1185350B (en) Oligomer-specific amyloid beta epitope and antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170222

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20170222

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20170309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171212

R150 Certificate of patent or registration of utility model

Ref document number: 6261621

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250